๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shanghai

3827 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Doxycycline for Helicobacter Pylori Rescue Treatment
NCT05874570Helicobacter Pylori Infection
Shanghai Jiao Tong University School of Medicine
Phase 4
368
Shanghai
2023-06-20
Recruiting
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
NCT05965557Lung Cancer
Geneplus-Beijing Co. Ltd.
Observational
100
Shanghai
2023-06-19
Recruiting
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
NCT05342194Intrahepatic Cholangiocarcinoma
DrugsGemcitabine Hydrochloride·Lenvatinib·Oxaliplatin·Cisplatin
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
480
Shanghai
2023-06-19
Recruiting
Strategies for Toddler ASD With Remote-therapy (STAR) Model for ASD
NCT05901558Autism Spectrum Disorder, Therapy
Children's Hospital of Fudan University
Not applicable
110
Shanghai
2023-06-15
Recruiting
Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer
NCT05904665Non-metastatic Colorectal Cancer, Circulating Tumor DNA Methylation
Fudan University
Not applicable
584
Shanghai
2023-06-15
Recruiting
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
NCT05913089Non Small Cell Lung Cancer
DrugsAnlotinib hydrochloride·Etoposide
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
58
Beijing, Fuzhou, Weifang, Shanghai, Taiyuan, Tianjin
2023-06-14
Recruiting
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
NCT06343064Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd.
Phase 1/2
156
Shanghai
2023-06-13
Recruiting
Efficacy and Safety Evaluation of Fecal Microbiota Transplantation in Irritable Bowel Syndrome
NCT05740319Irritable Bowel Syndrome
Shanghai Zhongshan Hospital
Not applicable
102
Shanghai
2023-06-10
Recruiting
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
NCT05912816Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC, PD-1antibody
RenJi Hospital
Phase 2
20
Shanghai
2023-06-10
Active, closed
Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors
NCT05700084Advanced Solid Tumor
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Recruiting
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
NCT05830123Osteosarcoma, Sarcoma
Hansoh BioMedical R&D Company
Phase 2
170
Beijing, Changsha, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
2023-06-08
Recruiting
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
NCT05883852HER2 Positive Early Breast Cancer
Fudan University
Phase 3
1,406
Shanghai
2023-06-07
Recruiting
Effects of Auricular Acupressure Versus Intermittent Dietary Restriction in Children With Gastric Heat and Dampness Obstruction
NCT05847478Obesity, Childhood
Children's Hospital of Fudan University
Not applicable
240
Shanghai
2023-06-07
Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3
DrugSafusidenib
Nuvation Bio Inc.
Phase 3
365
Beijing, Fuzhou, Guangzhou, Changsha, Shanghai, Chengdu
2023-06-05
Recruiting
The Pathogenesis and Prognostic Factors of Lymphoma
NCT06203652Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Shanghai Zhongshan Hospital
Observational
2,000
Shanghai
2023-06-05
Active, closed
Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control
NCT05894382Myopia, Progressive
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
236
Shanghai
2023-06-03
Recruiting
Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
NCT05910398Breast Cancer Invasive
DrugPyrotinib
RenJi Hospital
Phase 3
488
Shanghai
2023-06-01
Recruiting
An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells
NCT06249256Solid Tumor
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1
12
Shanghai
2023-06-01
Recruiting
Disitamab Vedotin (RC48-ADC) in Breast Cancer
NCT05851677Breast Cancer
RenJi Hospital
Observational
45
Shanghai
2023-06-01
Recruiting
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
NCT05876065Advanced Breast Cancer
Wenjin Yin
Not applicable
86
Shanghai
2023-06-01
Recruiting
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
NCT05901428Hormone Receptor Positive HER-2 Negative Breast Cancer
Fudan University
Phase 3
1,736
Shanghai
2023-06-01
Recruiting
PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)
NCT06074692Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone
Ruijin Hospital
Phase 2
86
Shanghai
2023-06-01
Recruiting
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
NCT05899621Follicular Lymphoma
Ruijin Hospital
Observational
332
Shanghai
2023-06-01
Recruiting
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
NCT05862064TNBC - Triple-Negative Breast Cancer
Fudan University
Phase 3
606
Shanghai
2023-06-01
Recruiting
Mechanism Study of Ventilator-Induced Lung Injury in Elderly People.
NCT06367946Ventilator-Induced Lung Injury
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
1,000
Shanghai
2023-06-01
Recruiting
Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial
NCT06114225Osteosarcoma
Ruijin Hospital
Phase 2
43
Shanghai
2023-06-01
Recruiting
Study of Brain-Gut Function Reconstruction After Intersphincteric Resection for Ultra-Low Rectal Tumors
NCT06082648Rectal Neoplasms
Huashan Hospital
Not applicable
57
Shanghai
2023-06-01
Active, closed
MRD in High-risk EBC
NCT06566729Breast Cancer
Shanghai Jiao Tong University School of Medicine
Observational
125
Shanghai
2023-06-01
Recruiting
Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer
NCT05861271Breast Cancer Stage I
Fudan University
Phase 2
1,008
Shanghai
2023-06-01
Recruiting
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
NCT05862285Cancer
DrugsIpatasertib·Tiragolumab·Divarasib·Entrectinib
Hoffmann-La Roche
Phase 3
100
Wuhan, XI 'an City, Shaanxi Province, Shanghai, Beijing, Changchun, Chengdu, Guangzhou, Hangzhou
2023-06-01
Recruiting
Consistency of Carotid Doppler Blood Flow and Thermodilution Technique
NCT05944146Cardiac Surgery
Shanghai Zhongshan Hospital
Not applicable
200
Shanghai
2023-05-31
Recruiting
Smart Flex Stent System for the Treatment Long Femoropopliteal Artery Lesions
NCT05894863Peripheral Arterial Disease
RenJi Hospital
Not applicable
120
Shanghai
2023-05-31
Active, closed
A Study of MHB036C for Advanced Solid Tumor
NCT06373406Advanced Solid Tumor
DrugMHB036C
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
200
Shanghai
2023-05-26
Recruiting
PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma
NCT05662540NK/T-cell Lymphoma
Ruijin Hospital
Not applicable
40
Shanghai
2023-05-26
Recruiting
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
NCT05859750Pancreatic Cancer
Drugs5-Fluorouracil/Leucovorin·Cadonilimab·Irinotecan·Nab-paclitaxel
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Recruiting
Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment
NCT05857800Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
2,000
Shanghai
2023-05-25
Recruiting
Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors
NCT05831033Solid Tumor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1
16
Shanghai
2023-05-23
By invitation
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
NCT05859997Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
DrugBRL-301
Bioray Laboratories
Not applicable
15
Shanghai
2023-05-17
Recruiting
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
NCT05319730Esophageal Squamous Cell Carcinoma
DrugsAntihistamine·Steroid mouthwash (dexamethasone·MK-4830·Equivalent)
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Recruiting
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
240
Beijing, Zhengzhou, Changsha, Shanghai, Hangzhou
2023-05-16
Recruiting
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
NCT05881265APL
Shanghai Jiao Tong University School of Medicine
Phase 2
30
Huai'an, Nanchang, Shanghai, Guangzhou
2023-05-15
Recruiting
Pilot Study of AuTNA I
NCT05853107Retinitis Pigmentosa
Eye & ENT Hospital of Fudan University
Not applicable
7
Shanghai
2023-05-12
Recruiting
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
NCT06080776Non-small Cell Lung Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 3
242
Shanghai
2023-05-11
Recruiting
Shanghai Non-pharmacological Intervention for Mild Cognitive Impairment and Mild Alzheimer's Disease
NCT05887674Mild Cognitive Impairment, Mild Dementia
Ruijin Hospital
Not applicable
180
Shanghai
2023-05-11
Recruiting
Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients
NCT05858684CAR-T Cell Therapy
DrugGC012F
RenJi Hospital
Phase EARLY_PHASE1
18
Shanghai
2023-05-11
Recruiting
Acute Ischemic Stroke EndoVascular Therapy: a Multicenter REGISTRY Study
NCT05864638Acute Ischemic Stroke, Large Vessel Occlusion, Thrombectomy, Thrombosis
Changhai Hospital
Observational
10,000
Shanghai
2023-05-10
Active, closed
A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC
NCT06443684Non Small Cell Lung Cancer
Shanghai Chest Hospital
Observational
305
Hefei, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Jinan, Shanghai
2023-05-08
Recruiting
Home Blood Pressure Intervention in the Community Trial
NCT05858944Home Blood Pressure
Shanghai Institute of Hypertension
Not applicable
10,000
Shanghai
2023-05-06
Recruiting
Gongji Pregnancy Endorine Cohort Study
NCT07125885Gestatiaonl Diabetes Mellitus, Thyroid Disease Pregnancy, Hyperglycemia in Pregnant Diabetic Patients
Shanghai General Hospital, China
Observational
3,000
Shanghai
2023-05-05
Recruiting
Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords
NCT05688488Glottic Web of Larynx, Laryngeal Stenosis, Glottic Carcinoma, Laryngeal Leucoplakia
DrugMitomycin C
Eye & ENT Hospital of Fudan University
Phase 1/2
100
Shanghai
2023-05-05
Recruiting
RC48-ADC in HER2-low Advanced Breast Cancer
NCT05831878Advanced Breast Cancer
DrugDisitamab Vedotin
RenJi Hospital
Not applicable
36
Shanghai
2023-05-04
Recruiting
The Application of Somatosensory Interactive Pelvic Floor Muscle Training for Stress Urinary Incontinence in Men Underwent Radical Prostatectomy
NCT06740071Prostate Cancer (Post Prostatectomy)
The University of Hong Kong
Not applicable
100
Shanghai
2023-05-01
Not yet open
Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment
NCT05717582Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer
DrugApalutamide
Fudan University
Phase 2
47
Shanghai
2023-05-01
Not yet open
Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion
NCT05807984Rectal Cancer, Recurrent
Xin Cai
Phase 2
31
Shanghai
2023-05-01
Active, closed
A Retrospective Study in Patients With Liver Injury After the Use of Novel Antineoplastic Agents
NCT06670391Liver Injury, Liver Injury, Drug-Induced
Drug Induced Liver Disease Study Group
Observational
2,000
Shanghai
2023-05-01
Active, closed
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer
NCT05585814Locally Advanced Rectal Cancer
DrugsOxaliplatin·Capecitabine·Pembrolizumab·Bevacizumab
Shanghai Changzheng Hospital
Phase 2
30
Shanghai
2023-05-01
Recruiting
Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors
NCT05834413Lung Cancer
Shanghai University of Traditional Chinese Medicine
Not applicable
367
Shanghai
2023-05-01
Active, closed
Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT05831891Non-clear Cell Renal Cell Carcinoma
RenJi Hospital
Phase 2
40
Shanghai
2023-05-01
Recruiting
Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect
NCT05206682Cesarean Section; Dehiscence
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
94
Shanghai
2023-05-01
Recruiting
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
NCT05806580Relapsed or Refractory B-cell Lymphoma
DrugRelma-cel
Ruijin Hospital
Phase 4
8
Shanghai
2023-05-01
Not yet open
Clinical Outcomes of CT-FFR Versus QFR-guided Strategy for Decision-Making in Patients With Stable Chest Pain
NCT05857904Angina, Stable, Coronary Artery Disease
Shanghai Zhongshan Hospital
Not applicable
4,648
Shanghai
2023-05
Not yet open
Real World Study of Linperlisib for Lymphoma Treatment
NCT05863871Focus on the Lymphoma Including B/T-cell Lymphoma
Ruijin Hospital
Observational
1,000
Shanghai, Tianjin
2023-05
Recruiting
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
NCT05918094Gastric Cancer
Sun Yat-sen University
Phase 3
540
Guangzhou, Guiyang, Harbin, Zhengzhou, Wuhan, Nanchang, Dalian, Shanghai
2023-04-30
Recruiting
CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
NCT05795335Breast Cancer
RenJi Hospital
Observational
172
Shanghai
2023-04-30
Active, closed
Study of CT071 Injection in RRMM or PPCL
NCT05838131Multiple Myeloma, Primary Plasma Cell Leukemia
Shanghai Changzheng Hospital
Phase EARLY_PHASE1
20
Shanghai
2023-04-28
Recruiting
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05806060Triple-Negative Breast Cancer
Fudan University
Phase 3
134
Shanghai
2023-04-25
Recruiting
Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
NCT05963490Microsatellite Stable Metastatic Colorectal Cancer
DrugsRegorafenib·Tislelizumab
Fudan University
Phase 2
108
Shanghai
2023-04-25
Recruiting
Effect of Gut Microbiome Intervention on Aging Via Oral FMT
NCT05598112Aging, Frailty
DrugFMT
Chinese Academy of Medical Sciences, Fuwai Hospital
Phase EARLY_PHASE1
210
Beijing, Shanghai, Hangzhou
2023-04-24
Active, closed
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer
DrugsVolrustomig·Rilvegostomig·Lenvatinib·Gemcitabine
AstraZeneca
Phase 2
294
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai
2023-04-24
Recruiting
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
NCT05785039Urinary System Tumor, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
76
Shanghai
2023-04-20
Recruiting
A Study of GLS-010 Plus Platinum-containing ChemotherapyยฑBevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
NCT05798819Persistent, Recurrent, or Metastatic Cervical Cancer
Guangzhou Gloria Biosciences Co., Ltd.
Phase 3
424
Shanghai
2023-04-20
Recruiting
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
NCT05738694Renal Cell Carcinoma, Neoadjuvant
ZHOU FANGJIAN
Phase 3
298
Beijing, Guangzhou, Hefei, Shanghai, Sichuan, Tianjin, Zhengzhou
2023-04-19
Recruiting
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT06702995Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
DrugsXNW5004·Enzalutamide
Evopoint Biosciences Inc.
Phase 1/2
307
Jinan, Shanghai
2023-04-19
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
DrugsPanitumumab·Folfiri·Nab-paclitaxel·Gemcitabine
Institut de Recherches Internationales Servier
Phase 1/2
554
Beijing, Jinan, Shanghai, Suzhou
2023-04-18
Recruiting
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
NCT05639647Gram-negative Bacterial Infections
Pfizer
Phase 2
48
Beijing, Guangzhou, Shanghai
2023-04-18
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Weill Medical College of Cornell University
Not applicable
2,300
Beijing, Changchun, Shanghai, Tianjin
2023-04-17
Active, closed
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
NCT06299124Breast Cancer, Advanced Solid Tumor
Regor Pharmaceuticals Inc.
Phase 1
40
Shanghai
2023-04-17
Recruiting
Comparison of the Therapeutic Effects of VR and VR + Metformin in the Treatment of Cesarean Section Scar Defect
NCT05205317Defect
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
100
Shanghai
2023-04-15
Recruiting
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
NCT05824988Mycobacterium Avium Complex, Mycobacterium Avium-Intracellulare Infection, Gram-Positive Bacterial Infections, Mycobacterium Infections
Shanghai Pulmonary Hospital, Shanghai, China
Observational
100
Shanghai
2023-04-14
Active, closed
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
NCT05645692Urothelial Cancer
DrugsTobemstomig·Tiragolumab·Atezolizumab
Hoffmann-La Roche
Phase 2
204
Beijing, Chengdu, Guangzhou, Shanghai
2023-04-13
Recruiting
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
NCT05701709Advanced Solid Tumors
DrugSHR-A2102
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
395
Shanghai
2023-04-06
Recruiting
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
NCT05751512Squamous Cell Carcinoma of the Head and Neck
DrugsBecotatug Vedotin·Methotrexate·Pemetrexed
Lepu Biopharma Co., Ltd.
Phase 3
180
Shanghai
2023-04-04
Active, closed
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906Biochemically Recurrent Prostate Cancer
DrugDarolutamide
Bayer
Phase 3
985
Beijing, Wuhan, Changsha, Nanjing, Shanghai, Chengdu, Tianjin, Hangzhou
2023-04-03
Not yet open
Effect of Incentive Integrated E-IBD Chronic Disease Management Model on the Quality of Life in IBD Patients
NCT05719766Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
200
Hangzhou, Huzhou, Shanghai, Shaoxing
2023-04-01
Recruiting
Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)
NCT06031246Lung Adenocarcinoma, Lymph Node Metastasis
Fudan University
Phase 3
634
Shanghai
2023-04-01
Recruiting
A Study of TIL in Advanced Solid Tumors (DFGD)
NCT06488950Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
DrugGC203 TIL
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
30
Shanghai
2023-04-01
Recruiting
The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics
NCT05791604Prader-Willi Syndrome
Children's Hospital of Fudan University
Not applicable
60
Shanghai
2023-04-01
Recruiting
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
NCT05736978AML, MRD
DrugsSelinexor·Azacitidine·Venetoclax
Shanghai Tong Ren Hospital
Phase 2
58
Shanghai
2023-03-31
Recruiting
Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)
NCT06031181Lung Adenocarcinoma, Frozen Section, Sublobar Resection
Fudan University
Phase 3
390
Shanghai
2023-03-31
By invitation
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
NCT05787418COVID-19
Huahui Health
Phase 3
1,200
Beijing, Shanghai
2023-03-31
Recruiting
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT05759793Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
12
Shanghai
2023-03-30
Recruiting
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
NCT05749588Triple-negative Breast Cancer
Fudan University
Phase 2
120
Shanghai
2023-03-30
Recruiting
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
NCT06041776Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Betta Pharmaceuticals Co., Ltd.
Phase 3
570
Beijing, Nanjing, Shanghai
2023-03-28
Active, closed
Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy
NCT05694598Bietti Crystalline Dystrophy
Shanghai Vitalgen BioPharma Co., Ltd.
Phase 1
12
Shanghai
2023-03-27
Recruiting
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
NCT05718895Advanced/Metastatic Solid Tumors
DrugATG-022
Antengene Biologics Limited
Phase 1
156
Beijing, Chengdu, Fuzhou, Hefei, Jinan, Lanzhou, Qingdao, Shanghai
2023-03-27
Recruiting
A Study of XZB-0004 in Patients With Solid Tumors
NCT05772455Advanced Solid Tumor, NSCLC
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
128
Shanghai
2023-03-24
Active, closed
Focus-out Glasses on Emmetropization in Chinese Children
NCT05689567Emmetropization, Myopia, Hyperopia
Children's Hospital of Fudan University
Not applicable
160
Shanghai
2023-03-23
Active, closed
A Phase I Clinical Study of the Safety๏ผŒ Tolerability๏ผŒPharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
NCT05781048Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
56
Shanghai
2023-03-23
Active, closed
SeQuent ยฎ Please CIS for the Treatment of INtracranial Atherosclerotic Stenosis
NCT06047964Stroke, Intracranial Atherosclerotic Stenosis
B. Braun Medical International Trading Company Ltd.
Not applicable
281
Beijing, Harbin, Nanyang, Changchun, Jining, Qingdao, Shanghai, Taiyuan
2023-03-23
Recruiting
A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients
NCT05823285Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1
150
Shanghai
2023-03-22
Rows per page Showing 3001–3100 of 3827
Previous 29 30 31 32 33 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=31

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,827 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,393 of the 3,827 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 737 have not yet opened recruitment, 588 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.